Phase 4
Completed N=641
Evaluation of Doxycycline Post-exposure Prophylaxis to Reduce Sexually Transmitted Infections in PrEP Users and HIV-infected Men Who Have Sex With Men
Source: ClinicalTrials.gov NCT03980223 ↗Enrolled (actual)
641
Serious AEs
0.9%
Results posted
Jul 2024
Primary outcomePrimary: Number of Quarterly Visits In Which an STI Was Detected — 61; 82; 36; 39 No. quarterly visits with STI event
◆ Published Evidence
Highly cited
443citations · ~148 / year
Postexposure Doxycycline to Prevent Bacterial Sexually Transmitted Infections.
Summary
The purpose of this study is to understand if taking an antibiotic called doxycycline by mouth as soon as possible after sexual contact without a condom can reduce the risk of sexually transmitted infections (STIs), including gonorrhea, chlamydia and syphilis. The study will also look at the safety of doxycycline PEP and the impact that PEP may have on the bacteria that cause STIs as well as on bacteria that normally live on the body. While doxycycline is approved by the Food and Drug Administration (FDA), taking doxycycline immediately after sexual contact to prevent infection is investigational and is not approved by the FDA for this use. Participants will take part in the study for 1 year.
Linked Publications (5)
-
Postexposure Doxycycline to Prevent Bacterial Sexually Transmitted Infections.
-
Impact of doxycycline post-exposure prophylaxis for sexually transmitted infections on the gut microbiome and antimicrobial resistome.
-
Doxycycline to prevent bacterial sexually transmitted infections in the USA: final results from the DoxyPEP multicentre, open-label, randomised controlled trial and open-label extension.
-
Doxycycline as Postsexual Exposure Prophylaxis: Use, Acceptability, and Associated Sexual Health Behaviors Among a Multi-Site Sample of Clinical Trial Participants.
-
"It's Been a Very Liberating Experience": Doxycycline Postexposure Prophylaxis for Sexually Transmitted Infection Prevention and Experiences With Sexual Pleasure by Men Who Have Sex With Men.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Quarterly Visits In Which an STI Was Detected |
61; 82; 36; 39 | — |
Eligibility Criteria
Inclusion Criteria
- Willing and able to give written informed consent
- Age ≥ 18 years
- Male sex at birth
- Previously HIV-diagnosed OR HIV-seronegative at the time of last test within the past month and a current prescription for PrEP (both daily or event-driven permitted) or plan to start PrEP within 30 days after the enrollment visit
- Condomless anal or oral sexual contact with ≥ 1 male sex-at-birth partners in the past 12 months
- Diagnosed with GC, CT or early syphilis (primary, secondary or early latent) in the past 12 months. Note: self report of STI is acceptable if documentation not available. If the participant reports an incident STI in the past year at the same clinic where the participant will be enrolled, this diagnosis should be confirmed by chart review prior to enrollment. If the diagnosis from this clinic cannot be confirmed, the participant should not be enrolled. If the STI was reported at a clinical site that is not the study site, and records cannot be obtained, self-report will suffice.
Note: Syphilis diagnosis within the last year refers to primary syphilis, secondary syphilis, and documented early latent syphilis (< 1 year since last syphilis diagnosis or negative test). Known late latent syphilis or latent syphilis of unknown duration would not qualify. Positive syphilis titers which represent serofast status and not active disease do not qualify as a syphilis diagnosis. Clinician judgement regarding qualifying syphilis diagnosis should be sought when the diagnosis of syphilis in the past year is not clear or if there is a question about serofast status vs. active infection.
Exclusion Criteria
- Allergy to tetracycline class
- Current medications which may impact doxycycline metabolism or that are contraindicated with doxycycline, as per the prescribing information. These include systemic retinoids, barbiturates, carbamazepine, and phenytoin.
- Current use of warfarin, as intermittent doxycycling use can lead to an unpredictable impact on INR
- Anticipated use of doxycycline during the coming 12 months for non-STI prevention (e.g., acne treatment).
Data sourced from ClinicalTrials.gov (NCT03980223) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.